A Mitochondria‐Targeted NIR‐II AIEgen Induced Pyroptosis for Enhanced Tumor Immunotherapy

Author:

Yu Kaiwu1,Ye Binglin2,Yang Huang3,Xu Xinxin1,Mao Zhengwei23,Zhang Qinghua1,Tian Mei4,Zhang Haoke3,Zhang Hong4,He Qinggang1ORCID

Affiliation:

1. College of Chemical and Biological Engineering Zhejiang University Hangzhou 310058 P. R. China

2. Department of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital Zhejiang University School of Medicine Zhejiang University Hangzhou 310009 P. R. China

3. MOE Key Laboratory of Macromolecular Synthesis and Functionalization Department of Polymer Science and Engineering Zhejiang University Hangzhou 310027 P. R. China

4. Department of Nuclear Medicine and PET Center The Second Hospital of Zhejiang University School of Medicine Hangzhou 310009 P. R. China

Abstract

AbstractCancer immunotherapy is a favorable strategy for facilitating anti‐tumor immunity, but it shows limited benefits in clinical practice owing to the immunosuppressive tumor microenvironment. Pyroptosis shows great immunostimulatory effect on tumor, whereas the lack of pyroptotic inducer with imaging property has restricted its progress in tumor theranostics. Herein, a mitochondria‐targeted aggregation‐induced emission (AIE) luminogen (TPA‐2TIN) with NIR‐II emission is designed for highly efficient induction of tumor cell pyroptosis. The fabricated TPA‐2TIN nanoparticles can be efficiently taken up by tumor cells and selectively accumulated in tumor for a long term observed by NIR‐II fluorescence imaging. More importantly, the TPA‐2TIN nanoparticles can effectively stimulate immune responses both in vitro and in vivo mediated by the mitochondrial dysfunctions and the subsequent activation of the pyroptotic pathway. Ultimately, the reversal of the immunosuppressive tumor microenvironment significantly enhances the immune checkpoint therapy. This study paves a new avenue for adjuvant immunotherapy of cancer.

Funder

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biomaterials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3